S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
Log in

NASDAQ:ARVN - Arvinas Stock Price, Forecast & News

$50.91
-0.38 (-0.74 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$49.68
Now: $50.91
$52.05
50-Day Range
$37.66
MA: $42.27
$51.59
52-Week Range
$14.06
Now: $50.91
$52.93
Volume208,750 shs
Average Volume228,917 shs
Market Capitalization$1.72 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.72
Arvinas, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARVN
CUSIPN/A
CIKN/A
Phone203-535-1456

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$14.32 million
Book Value$4.22 per share

Profitability

Net Income$-41,480,000.00
Net Margins-157.34%

Miscellaneous

Employees83
Market Cap$1.72 billion
Next Earnings Date3/24/2020 (Estimated)
OptionableNot Optionable

Receive ARVN News and Ratings via Email

Sign-up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.


5G Flaw Exposed: $5 Stock Holds Key To $12 Trillion Opportunity (Ad)


A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

Arvinas (NASDAQ:ARVN) Frequently Asked Questions

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

How were Arvinas' earnings last quarter?

Arvinas Inc (NASDAQ:ARVN) posted its earnings results on Monday, November, 4th. The company reported $0.21 EPS for the quarter, topping analysts' consensus estimates of ($0.46) by $0.67. The firm earned $30.05 million during the quarter, compared to analysts' expectations of $11.42 million. Arvinas had a negative net margin of 157.34% and a negative return on equity of 31.57%. View Arvinas' Earnings History.

When is Arvinas' next earnings date?

Arvinas is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Arvinas.

What price target have analysts set for ARVN?

10 brokers have issued 1 year price objectives for Arvinas' shares. Their forecasts range from $22.00 to $75.00. On average, they expect Arvinas' share price to reach $44.44 in the next twelve months. This suggests that the stock has a possible downside of 12.7%. View Analyst Price Targets for Arvinas.

What is the consensus analysts' recommendation for Arvinas?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arvinas.

Has Arvinas been receiving favorable news coverage?

Headlines about ARVN stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Arvinas earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Arvinas.

Are investors shorting Arvinas?

Arvinas saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 2,090,000 shares, an increase of 8.3% from the November 28th total of 1,930,000 shares. Based on an average daily volume of 405,200 shares, the days-to-cover ratio is presently 5.2 days. Currently, 10.0% of the shares of the stock are sold short. View Arvinas' Current Options Chain.

Who are some of Arvinas' key competitors?

What other stocks do shareholders of Arvinas own?

Who are Arvinas' key executives?

Arvinas' management team includes the folowing people:
  • Dr. John G. Houston Ph.D., CEO, Pres & Director (Age 59)
  • Mr. Sean A. Cassidy, CFO & Treasurer (Age 49)
  • Dr. Ian Taylor, Chief Scientific Officer (Age 56)
  • Dr. Craig M. Crews, Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
  • Dr. Andrew Crew, Chief Technology Officer (Age 54)

When did Arvinas IPO?

(ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

How do I buy shares of Arvinas?

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $50.91.

How big of a company is Arvinas?

Arvinas has a market capitalization of $1.72 billion and generates $14.32 million in revenue each year. The company earns $-41,480,000.00 in net income (profit) each year or ($25.45) on an earnings per share basis. Arvinas employs 83 workers across the globe.View Additional Information About Arvinas.

What is Arvinas' official website?

The official website for Arvinas is http://www.arvinas.com/.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]


MarketBeat Community Rating for Arvinas (NASDAQ ARVN)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  49 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  119
MarketBeat's community ratings are surveys of what our community members think about Arvinas and other stocks. Vote "Outperform" if you believe ARVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Featured Article: Diluted Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel